Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Advaxis, Inc.
Advaxis Receives US Patent and Trademark Office Approval on Act-A Protein Patent-Pending Rights
June 10th, 2009
The US Patent and Trademark office approved Advaxis Incorporated (OTCBB: ADXS) patent-application Compositions and Methods for Enhancing the Immunogenicity of Antigens (Application # US2005/0118184 A1). This patent application covers the use of Listeria monocytogenes (Lm) protein ActA and fragments of this protein for use in the creation of antigen fusion proteins. The ActA protein has been found to possess immuno-adjuvant properties. Advaxis’ proprietary technology is based, in part, upon bioengineered Lm that secretes antigen-adjuvant fusion proteins. The vaccines that Advaxis is developing, in both current and future clinical trials, make use of antigens fused to...
Source: Vaccine Weekly (2009-06-10)
|
